These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38948581)

  • 21. Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial.
    Thakkar A; Pradhan K; Duva B; Carreno JM; Sahu S; Thiruthuvanathan V; Campbell S; Gallego S; Bhagat TD; Rivera J; Choudhary G; Olea R; Sabalza M; Shapiro LC; Lee M; Quinn R; Mantzaris I; Chu E; Will B; Pirofski LA; Krammer F; Verma A; Halmos B
    Elife; 2023 Mar; 12():. PubMed ID: 36975207
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Media Reporting Relating to COVID-19 Vaccination as a Driver of Vaccine Hesitancy Prior to the Second Wave of the COVID-19 Pandemic in India: A Content Analysis of Newspaper and Digital Media Reports.
    Basu S; Sharma H
    Cureus; 2023 Mar; 15(3):e36750. PubMed ID: 37123709
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Will People Accept a Third Booster Dose of the COVID-19 Vaccine? A Cross-Sectional Study in China.
    Sun Y; Dai H; Wang P; Zhang X; Cui D; Huang Y; Zhang J; Xiang T
    Front Public Health; 2022; 10():914950. PubMed ID: 35903387
    [TBL] [Abstract][Full Text] [Related]  

  • 24. What is the Safety of COVID-19 Vaccines in Immunocompromised Patients? Results from the European "Covid Vaccine Monitor" Active Surveillance Study.
    Bellitto C; Luxi N; Ciccimarra F; L'Abbate L; Raethke M; van Hunsel F; Lieber T; Mulder E; Riefolo F; Villalobos F; Thurin NH; Marques FB; Morton K; O'Shaughnessy F; Sonderlichová S; Farcas A; Janneke GE; Sturkenboom MC; Trifirò G
    Drug Saf; 2024 Jun; ():. PubMed ID: 38907947
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity of ChAdOx1 (Covishield) Booster Dose in Healthcare Providers: A Pre-Post Study.
    Meher T; Pradhan SK; Hatei SP; Majhi SC; Panda A; Mund SR; Mishra SK
    Cureus; 2023 Oct; 15(10):e46370. PubMed ID: 37920622
    [TBL] [Abstract][Full Text] [Related]  

  • 26. COVID-19: vaccination vs. hospitalization.
    Uzun O; Akpolat T; Varol A; Turan S; Bektas SG; Cetinkaya PD; Dursun M; Bakan N; Ketencioglu BB; Bayrak M; Baris SA; Guner R; Gunal O; Nural S; Deniz PP; Toprak OB; Ozkan G; Gumus A; Kerget F; Ercelik M; Ataoglu O; Yuksel A; Ates G; Kutsoylu OE; Kose N; Kizilirmak D; Keskin S; Gultekin O; Coskun N; Yilmaz ES; Uslu S; Basyigit İ; Ergan B; Deveci F; Yakar MN; Zuhur C; Sagcan G; Yuce ZT; Kuluozturk M; Sezgin ME; Sezgin ENA; Havlucu Y; Cuhadaroglu C; Kilinc O; Boyaci H; Altunay H; Akti M; Dursun ZB; Kalem AK; Isik SA; Akyildiz L; Aykac N; Almaz MS; Kokturk N; Itil O
    Infection; 2022 Jun; 50(3):747-752. PubMed ID: 34984646
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of Covid-19 vaccines (CovishieldTM and Covaxin ®) in healthcare workers in Mumbai, India: A retrospective cohort analysis.
    Contractor A; Shivaprakash S; Tiwari A; Setia MS; Gianchandani T
    PLoS One; 2022; 17(10):e0276759. PubMed ID: 36301977
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody Response to COVID-19 Vaccines in Healthcare Workers: Which One is More Successful? Homologous or Heterologous?
    Karakoc ZC; Tascioglu D; Ediz B; Caglan M; Hancer VS; Tugrul TS; Simsek BP
    Sisli Etfal Hastan Tip Bul; 2023; 57(2):216-223. PubMed ID: 37899804
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5-11 Years - United States, October 12-January 1, 2023.
    Hause AM; Marquez P; Zhang B; Su JR; Myers TR; Gee J; Panchanathan SS; Thompson D; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2023 Jan; 72(2):39-43. PubMed ID: 36634021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety Monitoring of COVID-19 mRNA Vaccine First Booster Doses Among Persons Aged ≥12 Years with Presumed Immunocompromise Status - United States, January 12, 2022-March 28, 2022.
    Hause AM; Baggs J; Marquez P; Abara WE; Baumblatt JG; Thompson D; Su JR; Myers TR; Gee J; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2022 Jul; 71(28):899-903. PubMed ID: 35834416
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacovigilance Study of Anticancer Drugs in a Tertiary Care Teaching Hospital in North India: A Retrospective Study.
    Kumar R; Jindal A; Garg P; Kaur A; Kumar S; Tilak Raj R; Singh S
    Cureus; 2023 Sep; 15(9):e44984. PubMed ID: 37822427
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of safety and adverse drug reactions of COVID vaccination in the South Indian population: An observational prospective cross-sectional study.
    Manda A; Koya P; Pallem R; Mohd D; Thatikonda K; Venkateshwarlu K
    Ann Med Surg (Lond); 2022 Dec; 84():104948. PubMed ID: 36536701
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acceptance and adverse effects following COVID-19 vaccination among the health care workers at a health care centre in the most backward district of India.
    Sharma A; Jain M; Vigarniya M
    J Family Med Prim Care; 2022 Jun; 11(6):3224-3229. PubMed ID: 36119236
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adverse events following Covaxin administration among adolescents (15-18 years) - A pharmacovigilance study in a district in Northern India.
    Deb T; Kaur M; Misra S; Verma N; Sindhu N; Kairi J
    J Family Med Prim Care; 2024 Mar; 13(3):838-840. PubMed ID: 38736802
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of the Knowledge, Attitudes, and Practices of Indian Medical Students Towards Coronavirus Disease 2019 (COVID-19) After Two Doses of Vaccination and Their Approach Towards the Third (Booster) Dose.
    Banerjee S; Sarvottam K; Gupta AK
    Cureus; 2024 Mar; 16(3):e55588. PubMed ID: 38576675
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial.
    Hardt K; Vandebosch A; Sadoff J; Le Gars M; Truyers C; Lowson D; Van Dromme I; Vingerhoets J; Kamphuis T; Scheper G; Ruiz-Guiñazú J; Faust SN; Spinner CD; Schuitemaker H; Van Hoof J; Douoguih M; Struyf F;
    Lancet Infect Dis; 2022 Dec; 22(12):1703-1715. PubMed ID: 36113538
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Willingness to pay for booster dose of COVID-19 vaccine among healthcare workers in Taizhou,China.
    Pan SJ; Yang YP; Zhang MX; Tung TH
    Hum Vaccin Immunother; 2022 Nov; 18(5):2063629. PubMed ID: 35522922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Willingness to accept a second COVID-19 vaccination booster dose among healthcare workers in Italy.
    Della Polla G; Miraglia Del Giudice G; Folcarelli L; Napoli A; Angelillo IF;
    Front Public Health; 2022; 10():1051035. PubMed ID: 36568799
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial.
    Dixit A; Bennett R; Ali K; Griffin C; Clifford RA; Turner M; Poston R; Hautzinger K; Yeakey A; Girard B; Zhou W; Deng W; Zhou H; Schnyder Ghamloush S; Kuter BJ; Slobod K; Miller JM; Priddy F; Das R;
    Lancet Infect Dis; 2024 Jul; 24(7):687-697. PubMed ID: 38518789
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dynamicity and persistence of severe acute respiratory syndrome coronavirus-2 antibody response after double dose and the third dose with BBV-152 and AZD1222 vaccines: A prospective, longitudinal cohort study.
    Parai D; Choudhary HR; Dash GC; Behera S; Mishra N; Pattnaik D; Raghav SK; Mishra SK; Sahoo SK; Swain A; Mohapatra I; Pattnaik M; Moharana A; Jena SR; Praharaj I; Subhadra S; Kanungo S; Bhattacharya D; Pati S
    Front Microbiol; 2022; 13():942659. PubMed ID: 36016787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.